In This Store
Category:Intermediates > Chiral Intermediates
Product Name:Betadex sulfobutyl ether sodium 182410-00-0
CAS No.:182410-00-0
Standard:USP
Price(USD):USD211-325
Company:Shandong Binzhou Zhiyuan Biotechnology Co., Ltd.
Grade: Injection Grade
Factory Location: Binzhou
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe
Monthly Production Capacity: 5000kg
Packaging Information: 500g/bag , 1kg/bag, 10kg/drum , 20kg/drum or customized
Delivery Lead Time: Within one week
Sample Provided: yes
Payment Terms: T/T
Basic information
Name: Betadex sulfobutyl ether sodium
CAS: 182410-00-0
Molecular formula :C42H70-nO35 (C4H8O3S Na)n
Molecular weight: 1135+158n
Qaulity : Injection grade
Standard : USP41
Package: 500g/bag , 1kg/bag, 10kg/drum , 20kg/drum or customized
The role in ophthalmic medicine
Betadex sulfobutyl ether sodium has little stimulation on cornea and can reduce the irritation of drugs on the eyeball, so it is very suitable for the preparation of eye drops with physiological pH and osmotic pressure requirements.
Ganciclovir was soluble in water, but the water solubility was significantly affected by pH, more easily in dissolved under acidic conditions. The pH and osmotic pressure of the eyedrops are strictly required. The results showed that the Betadex sulfobutyl ether sodium in the prescription significantly reduced the eye irritation of ganciclovir, and the inclusion of Betadex sulfobutyl ether sodium on the drug could increase the biocompatibility of the eye drops.
O,O’-Dipropionyl-(1,4-xylylene)bispilocarpate is a precursor of trabeculin, a drug for glaucoma treatment. It has a strong irritation to the eye and affects its clinical application. After adding Betadex sulfobutyl ether sodium to the prescription of the eye drops, it was found that the irritation of Betadex sulfobutyl ether sodium eye drops to rabbit eyes was significantly reduced within the range of 24 ~ 36mmol. L-1. The mechanism may be that when the drug forms a inclusion compound with Betadex sulfobutyl ether sodium, the inclusion compound can slowly release the drug in the eye, so as to reduce the local concentration of the free drug and reduce or eliminate the eye irritation caused by the rapid absorption or precipitation of the drug.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: